|1.||Wachters, Floris M: 1 article (06/2010)|
|2.||de Vries, Elisabeth G E: 1 article (06/2010)|
|3.||Maurer, Marina: 1 article (06/2010)|
|4.||Maring, Jan Gerard: 1 article (06/2010)|
|5.||Groen, Harry J M: 1 article (06/2010)|
|6.||Uges, Donald R A: 1 article (06/2010)|
|7.||Danesi, R: 1 article (06/2002)|
|8.||Donati, S: 1 article (06/2002)|
|9.||Fogli, S: 1 article (06/2002)|
|10.||Del Tacca, M: 1 article (06/2002)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/1991 - "Pharmacokinetic analysis of epirubicin and its metabolites epirubicinol and 7-deoxy-13-dihydro-epirubicinol aglycone during the first and the fourth courses of treatment was performed in 78 patients with metastatic breast cancer. "
07/01/1997 - "Our study demonstrates that (1) the MTD is epirubicin 90 mg/m2 and paclitaxel 200 mg/m2; (2) no clear relationship exists between pharmacokinetic data of paclitaxel and myelosuppression, while the increase in the dose of paclitaxel is associated with a reduction in epirubicinol plasma levels; and (3) the association is feasible, with low cardiotoxicity, and has a high activity in metastatic breast cancer."
06/01/2002 - "The objectives of this study were to investigate the disposition of gemcitabine, epirubicin, paclitaxel, 2',2'-difluorodeoxyuridine and epirubicinol, and characterize the pharmacokinetic and pharmacodynamic profile of treatment in patients with breast cancer. "
05/01/2002 - "Plasma concentrations of paclitaxel, epirubicin and epirubicinol were measured and the relationship between neutropenia and drug pharmacokinetics was evaluated using a sigmoid maximum effect (Emax) model. "
06/01/2002 - "Paclitaxel and/or its vehicle, Cremophor EL, interferes with the disposition and renal excretion of epirubicin and epirubicinol; gemcitabine has no affect on epirubicin and paclitaxel plasma pharmacokinetics and renal excretion of epirubicin, while neutropenia is not enhanced by gemcitabine."
01/01/1987 - "In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. "
05/01/1986 - "The plasma levels of epirubicin and its metabolite, epirubicinol, were measured by HPLC following intravenous administration of epirubicin to cancer patients at doses of 40, 60, 80, and 100 mg/m2. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)